Press Release: European Medicines Agency recommends first medical treatment for removal of eschar from severe burn wounds

Author (Corporate)
Series Title
Series Details EMA/CHMP/406865/2012 (21.9.12)
Publication Date 21/09/2012
Content Type

The European Medicines Agency, on 21 September 2012, recommended approval of NexoBrid, an orphan-designated medicine, for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burn. Eschar is the dried-out, thick, leathery, black necrotic tissue that covers severe burn wounds. Its removal is essential to initiate the wound healing process and prevent further complications such as infections in burn victims.
Source Link http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/09/news_detail_001610.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/406865/2012 (21.9.12) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/09/WC500132889.pdf
Subject Categories
Countries / Regions